Use of MS drug expanded to include children

May 14, 2018

(HealthDay)—The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older.

It's the first multiple sclerosis drug approved for children, the agency said in a news release. The drug was approved in 2010 to treat adults with relapsing MS.

Multiple is a chronic central nervous system disease that disrupts communication between the brain and other parts of the body. It occurs more frequently in women than men. The inflammatory autoimmune disease leads to a progressive decline in motor function. Initial symptoms usually emerge between ages 20 and 40, the FDA said.

But an estimated 8,000 to 10,000 children and teens in the United States have MS, and up to 5 percent of people have symptom onset before age 18, the agency said.

In clinical testing among more than 200 children ages 10 to 17, 86 percent of trial participants given Gilenya were free after 24 months, compared to 46 percent of patients given the drug interferon beta-1a.

Gilenya's side effects in were similar to those seen in adults, including headache, elevated liver enzymes, diarrhea, cough, sinusitis, and pain in the back, abdomen, arms and legs, the FDA said.

More severe risks include slowed heart rate, serious infections, vision problems, respiratory problems, liver injury and . The shouldn't be taken by women who are pregnant or expecting to become pregnant because it can harm a developing fetus.

Gilenya is produced by the Swiss drugmaker Novartis.

Explore further: Drug duo approved for aggressive thyroid cancer

More information: The FDA has more about this approval.

Related Stories

Drug duo approved for aggressive thyroid cancer

May 5, 2018
(HealthDay)—Two anti-cancer drugs administered together have been approved by the U.S. Food and Drug Administration to treat an inherited form of thyroid cancer.

FDA investigating PML in patient taking MS drug

August 31, 2013
(HealthDay)—The U.S. Food and Drug Administration is investigating the possible association between a rare brain infection and the multiple sclerosis (MS) drug Gilenya (fingolimod), according to a drug safety alert issued ...

Novartis drug investigated after 11 deaths

January 20, 2012
A multiple sclerosis drug made by industry giant Novartis is under investigation after at least 11 patients taking the medicine died.

FDA approves first drug for rare form of rickets

April 23, 2018
(HealthDay)—Ultragenyx Pharmaceutical Inc.'s Crysvita (burosumab-twza) has been approved by the U.S. Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH).

Novartis profit slips as key drug goes generic

October 25, 2016
Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya.

Aubagio approved for multiple sclerosis

September 13, 2012
(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.